The Oncology Institute, Inc. (TOI) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.
The consensus price target is $5.00, representing an upside of 47.9% from the current price $3.38.
Analysts estimate Earnings Per Share (EPS) of $-0.36 and revenue of $0.42B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.00 vs est $-0.36 (beat +99.7%). 2025: actual $-0.54 vs est $-0.59 (beat +8.1%). Analyst accuracy: 0%.
TOI Stock — 12-Month Price Forecast
$5.00
▲ +47.93% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for The Oncology Institute, Inc., the price target is $5.00.
The average price target represents a +47.93% change from the last price of $3.38.
TOI Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to The Oncology Institute, Inc. in the past 3 months
EPS Estimates — TOI
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.00
vs Est –$0.36
▲ 35,900.0% off
2025
Actual –$0.54
vs Est –$0.59
▲ 8.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — TOI
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.393B
vs Est $0.415B
▼ 5.4% off
2025
Actual $0.503B
vs Est $0.501B
▲ 0.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
